Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Overall pathological complete response rates in the three treatment arms

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Response TCL (n = 10) TCH (n = 36) TCHL (n = 33)
pCR (no invasive cancer in the breast or LNs) 2 (20%) 19 (52.8%) 17 (51.5%)
p = 0.0839 (TCL vs. TCH); 1.000 (TCH vs. TCHL); 0.1488 (TCL vs. TCHL)
  1. Abbreviations: LN Lymph node, pCR Pathological complete response, TCH Docetaxel, carboplatin, and trastuzumab, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib, TCL Docetaxel, carboplatin, lapatinib
  2. Overall pCR rates within each treatment arm following 6 cycles of neoadjuvant TCL, TCH or TCHL